SRM

Across TCGA pan-cancer cohorts, SRM mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SRM data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SRM mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SRM expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where SRM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.739	0.938	<.001	88	view →
LUAD	DFS	Median	All	0.970	0.830	.009	11	view →
PDAC	DFS	Median	III,IV	0.233	0.473	.014	7	view →
COAD	DFS	Median	IV	0.432	0.944	.012	6	view →
UCEC	OS	Tertile	All	0.926	1.000	.046	4	view →
HNSC	DFS	Quartile	All	0.907	0.735	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SRM–CCRCC (OS)

Open the CCRCC breakdown →